[go: up one dir, main page]

NO975953D0 - Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene - Google Patents

Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene

Info

Publication number
NO975953D0
NO975953D0 NO975953A NO975953A NO975953D0 NO 975953 D0 NO975953 D0 NO 975953D0 NO 975953 A NO975953 A NO 975953A NO 975953 A NO975953 A NO 975953A NO 975953 D0 NO975953 D0 NO 975953D0
Authority
NO
Norway
Prior art keywords
adenoviruses
aavs
preparation
cell line
pharmaceutical preparations
Prior art date
Application number
NO975953A
Other languages
English (en)
Other versions
NO975953L (no
Inventor
Martine Latta
Cecile Orsini
Michel Perricaudet
Edouard Proust
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO975953D0 publication Critical patent/NO975953D0/no
Publication of NO975953L publication Critical patent/NO975953L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO975953A 1995-06-23 1997-12-18 Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene NO975953L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9507570A FR2735789B1 (fr) 1995-06-23 1995-06-23 Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
PCT/FR1996/000968 WO1997000947A1 (fr) 1995-06-23 1996-06-20 Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
NO975953D0 true NO975953D0 (no) 1997-12-18
NO975953L NO975953L (no) 1997-12-18

Family

ID=9480335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975953A NO975953L (no) 1995-06-23 1997-12-18 Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene

Country Status (16)

Country Link
US (3) US20020098165A1 (no)
EP (1) EP0833896A1 (no)
JP (1) JP3821846B2 (no)
KR (1) KR100514070B1 (no)
AU (1) AU716508B2 (no)
BR (1) BR9608965A (no)
CA (1) CA2222270A1 (no)
CZ (1) CZ295934B6 (no)
FR (1) FR2735789B1 (no)
HU (1) HU224679B1 (no)
IL (2) IL122710A0 (no)
MX (1) MX9709549A (no)
NO (1) NO975953L (no)
SK (1) SK174297A3 (no)
WO (1) WO1997000947A1 (no)
ZA (1) ZA965306B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
SI1445322T2 (sl) 1995-06-15 2012-10-30 Crucell Holland Bv Pakirni sistemi za humani rekombinantni adenovirus za gensko terapijo
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems
EP0931158A1 (en) * 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP0859008A3 (en) * 1997-02-18 2000-04-05 Hoechst Aktiengesellschaft Nucleic acid construct for the cell cycle regulated expression of structural genes
EP0860445A1 (en) 1997-02-18 1998-08-26 Hoechst Aktiengesellschaft New nucleotide sequences for the cell cycle regulated expression of structural genes
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU6151899A (en) 1998-09-23 2000-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of treating chronic pain
CA2347369A1 (en) * 1998-10-19 2000-04-27 Powderject Vaccines, Inc. Minimal promoters and uses thereof
CN1074459C (zh) * 1998-11-25 2001-11-07 马丁 重组腺病毒－胸苷激酶构建体及其获得方法和用途
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7115391B1 (en) * 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
EP1377672A2 (en) * 2001-02-23 2004-01-07 Novartis AG Vector constructs
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
KR100697245B1 (ko) * 2005-03-28 2007-03-21 한국생명공학연구원 중금속 유도성 프로모터와 이의 생물공학적 활용
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
DK3207130T3 (da) 2014-10-14 2019-11-11 Halozyme Inc Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
CN110072546B (zh) 2016-09-20 2023-10-31 勃林格殷格翰动物保健有限公司 新的猪流感疫苗
EA201990718A1 (ru) 2016-09-20 2019-10-31 Векторы аденовируса собачьих
BR112019005516A2 (pt) 2016-09-20 2019-06-18 Boehringer Ingelheim Vetmedica Gmbh novo sítio de inserção do ehv orf70
AU2017329672B2 (en) 2016-09-20 2023-07-27 Boehringer Ingelheim Vetmedica Gmbh New promoters
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3580341A4 (en) 2017-02-09 2020-11-04 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
LT3596116T (lt) 2017-03-16 2023-11-10 Alpine Immune Sciences, Inc. Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
EP3697810A2 (en) 2017-10-18 2020-08-26 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
ES2966045T3 (es) 2018-06-04 2024-04-18 Calidi Biotherapeutics Inc Vehículos basados en células para la potenciación de la terapia viral
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR20210091740A (ko) 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
CN113891934A (zh) 2018-11-21 2022-01-04 因达普塔治疗公司 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2020229875B2 (en) 2019-02-27 2025-01-16 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230190801A1 (en) 2020-04-22 2023-06-22 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
US20230203535A1 (en) * 2020-05-26 2023-06-29 St. Jude Children's Research Hospital, Inc. Recombinant P5 Promoter for Use in Reducing DNA Contamination of AAV Preparations
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592997A1 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
ZA965306B (en) 1997-01-24
EP0833896A1 (fr) 1998-04-08
CZ295934B6 (cs) 2005-12-14
KR100514070B1 (ko) 2005-12-21
FR2735789B1 (fr) 1997-07-25
JP3821846B2 (ja) 2006-09-13
AU716508B2 (en) 2000-02-24
KR19990028307A (ko) 1999-04-15
SK174297A3 (en) 1998-09-09
CZ413097A3 (cs) 1998-03-18
HUP9900050A3 (en) 2001-08-28
NO975953L (no) 1997-12-18
JPH11507835A (ja) 1999-07-13
US20030039634A1 (en) 2003-02-27
HU224679B1 (hu) 2005-12-28
FR2735789A1 (fr) 1996-12-27
US7033826B2 (en) 2006-04-25
AU6363996A (en) 1997-01-22
IL122710A (en) 2006-10-05
US6420170B1 (en) 2002-07-16
MX9709549A (es) 1998-03-31
US20020098165A1 (en) 2002-07-25
IL122710A0 (en) 1998-08-16
CA2222270A1 (fr) 1997-01-09
WO1997000947A1 (fr) 1997-01-09
HUP9900050A1 (hu) 1999-04-28
BR9608965A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
NO975953D0 (no) Rekombinante adenoviruser, deres anvendelse for fremstilling av AAV'er, komplementær cellelinje samt farmasöytiske preparater inneholdende adenovirusene
IL122347A0 (en) Recombinant adenovirus and adeno-associated virus cell lines methods of production and pharmaceutical compositions containing the same
GB2292080B (en) Cosmetic formulations having keratolytic and/or anti-acne activity,their preparations and use
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
NO982580L (no) Nye taxoider, deres fremstilling samt farmas°ystiske preparater inneholdende taxoidene
NO990793L (no) 7<alfa>-(<Epsilon>-aminoalkyl)-°stratriener, fremgangsmÕte for fremstilling av disse, farmas°ytiske preparater inneholdende disse, samt deres anvendelse for fremstilling av legemidler
FI102132B1 (fi) ATM-solun otsikkokenttien käyttö radiovälitteisessä ATM-tiedonsiirrossa
AU5588298A (en) Adeno-associated viral vector-mediated delivery of dna to cells of the liver
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
NO942910L (no) Nye baccatin-III- og 10-desacetyl-baccatin-III-derivater, deres fremstillinger, samt farmasöytiske preparater inneholdende derivatene
NO20016247L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
DK439589D0 (da) Fluorsubstituerede 4'-demethylepipodophyllotoksinderivater samt farmaceutiske praeparater indeholdende samme
AU5650894A (en) Tachyquinine antagonists, their preparation and use in pharmaceutical formulations
FR2680372B1 (fr) Preparations aqueuses stables d'enzymes et leur utilisation.
AU2408397A (en) Ob protein receptor genes and use of the same
NO305750B1 (no) Substituerte benzensulfonylureaer og deres anvendelse for fremstilling av farmas°ytiske preparater samt farmas°ytiske preparater inneholdende forbindelsene
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
AU6720698A (en) Pharmaceutical compositions containing colostrum and the use of colostrum for the treatment of hair loss
NO965370L (no) Substituerte kromanylsulfonyl(tio)ureaer, fremgangsmåter til deres fremstilling, deres anvendelse i farmasöytiske preparater samt farmasöytiske preparater inneholdende forbindelsene
BR9708654A (pt) Derivados de 3-[(1,2,3,4-tetrahidroisoquinolein-2-il)metil]-8-azabici clo [3.2.1]octano sua preparacão e sua aplicacão em terapia
NO308793B1 (no) Ortosubstituerte benzoylguanidiner, deres anvendelse for fremstilling av medikamenter samt legemidler inneholdende forbindelsene
王保树 Difficulties in the Corporatization of State-owned Enterprises and Legal Considerations
Macaulay Regulation of gene expression in Shope fibroma virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application